Ann Arbor, Mich. September 5, 2018—Strata Oncology, Inc. today announced it is participating as a CLIA-certified/accredited laboratory for the precision medicine cancer trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131). The objective of this ongoing phase II trial, co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), is to match genetic abnormalities of tumors with suitable targeted therapy, regardless of cancer type. Through the collaboration, Strata Oncology is designated to identify potential candidates from participating NCI-MATCH clinical sites in its Precision Oncology Network, for enrollment onto NCI-MATCH treatment arms. Tumor testing by a designated lab is the only pathway for patients to enroll into the trial.
“The size and scope of NCI-MATCH provided inspiration for Strata’s highly-scaled, systematic approach to precision medicine clinical research,” said Dan Rhodes, PhD, CEO of Strata Oncology. “Universal access to tumor profiling paired with robust trial-matching is a core feature of Strata’s precision medicine platform, so we believe our health system partners are uniquely positioned to make a significant contribution to the success of this important study.”
StrataNGS is utilized in routine clinical care across the Strata Precision Oncology Network, a network of 11 leading health systems committed to advancing research and patient care through a clinical-research driven model for precision oncology. The test is available at no cost to 100,000 patients with advanced cancer through the Strata Trial, an observational protocol providing tumor molecular profiling and matching to a portfolio of clinical trials. Network members deploy a streamlined, data-driven precision medicine workflow that enables efficient identification of eligible patients, universal access to StrataNGS, and proactive enrollment on precision therapy trials.
Read full article here.